Follow-The-Filings

Security

BNTC

Benitec Biopharma Inc. · COM NEW

Equity holders as of 2026 Q1 (each manager’s latest book)

5 owners max 0.0% (Dmitry Balyasny - Balyasn...)

grid → activity →
owners 5
max % 0.0%
tracked value $32M
qoq A 5

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% Add 0.00 pp 653,835 $7M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Add 0.00 pp 1,174,758 $16M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Add 0.00 pp 652,064 $7M hist
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 171,722 $2M hist
Marshall Wace - Marshall Wace, LLP 2026 Q1 0.0% Add 0.00 pp 71,832 $765 hist

5 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $75,000 $0.00 —
Gross profit — — —
Gross margin — — —
Net income -$19.56M -$21.75M -$37.92M
Net margin * -26082.7% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $3.73M $51.67M $98.52M
Total non-current assets * $735,000 $536,000 $1.07M
Total assets $4.46M $52.21M $99.59M
Total current liabilities $3.98M $4.92M $1.8M
Total non-current liabilities * $284,000 $38,000 $495,000
Total equity $202,000 $47.25M $97.3M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$18.01M -$19.4M -$23.59M
Cash from investing -$1,000 -$179,000 -$18,000
Cash from financing $16.02M $68.03M $70.48M
Net change in cash -$1.59M $48.44M $46.93M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders